CJC-1295: human evidence, DAC, safety and UK status
Get practical health advice and updates on Puri Pharmacy services straight to your inbox.
CJC-1295 is an investigational peptide developed to stimulate growth hormone release. Early human research showed changes in growth hormone and IGF-1, but those results do not establish better recovery, muscle strength, sleep or longevity. It is not a licensed UK treatment for these wellness purposes. Online “DAC” and “no DAC” labels create an additional problem: evidence about one preparation cannot simply be transferred to another.
- Hormone activity is evidence of a biological effect, not automatically a health benefit.
- The long-acting preparation studied in early trials matters; a similar label is not proof of equivalence.
- Long-term benefit and safety for wellness use remain unestablished.
- CJC-1295 is prohibited at all times under the 2026 WADA List.
- Persistent symptoms deserve assessment rather than a self-selected hormone intervention.
Puri Pharmacy’s position: we do not sell, supply or prescribe the experimental research peptides discussed here. Their proposed wellness uses remain investigational. Licensed peptide medicines also exist, including insulin; that does not validate unrelated research products. We recognise that people may already be using these substances and want them to seek appropriate advice without judgement. Information, supervision and blood tests cannot make an inadequately studied product safe.
What is CJC-1295?
CJC-1295 is an analogue of growth hormone-releasing hormone, usually shortened to GHRH. An analogue is a molecule designed to resemble another molecule while changing some of its properties. GHRH signals the pituitary gland to release growth hormone. IGF-1, or insulin-like growth factor 1, is another part of the growth-hormone signalling system.
The original clinical research concerned a long-acting preparation. The aim was to prolong the signalling effect compared with short-lived GHRH. This makes CJC-1295 different from directly administering growth hormone, but “stimulates your own hormones” is not a safety guarantee. Altering the body’s production is still a pharmacological intervention.
The 2006 Teichman study is a useful starting point for understanding the research. Its purpose was to examine drug behaviour, hormone responses and short-term safety—not to establish a general anti-ageing treatment.
Why DAC and “no DAC” need careful interpretation
DAC refers to a drug affinity complex used to extend a peptide’s action through albumin binding. Albumin is a blood protein. Online material also uses “CJC-1295 without DAC” or “no DAC” for related preparations. These names are often presented as if they describe interchangeable versions with the same evidence.
That assumption is not justified. The FDA’s December 2024 scientific briefing on CJC-1295-related substances distinguishes forms and highlights uncertainty about which form some marketed mixtures contain. This is a scientific identity issue; the FDA document does not determine UK law.
Before using a study to support a claim, ask whether its substance, chemical modification, formulation and route match the product being discussed. An abbreviation on a sales page does not settle any of those questions. Nor does a seller’s assertion that one version is “cleaner” establish comparative safety.

What did the human research actually show?
Teichman and colleagues reported two randomised, placebo-controlled, double-blind trials lasting 28 and 49 days in healthy adults aged 21–61. The main measurements concerned growth hormone, IGF-1 and the drug’s behaviour in the body. Hormone concentrations rose and the effects persisted. The report described no serious adverse reactions during those studies. Read the study abstract and publication details.
Those findings need to be kept within their limits. A few weeks of observation in selected volunteers cannot establish safety over years or in people with substantial medical problems. A rise in a laboratory marker does not answer whether someone becomes stronger, recovers from an injury sooner or develops fewer illnesses.
The difference between a marker and a meaningful outcome
Imagine a study records higher IGF-1 but does not measure return to sport. It would be reasonable to say that the intervention changed IGF-1 in that setting. It would not be reasonable to advertise a shorter rehabilitation time on the basis of that result. The missing outcome cannot be supplied by a convincing explanation of the mechanism.
The same distinction applies to sleep and ageing. A claim about sleep needs relevant sleep outcomes. A claim about healthier ageing needs meaningful health outcomes over an appropriate period. “More youthful hormone levels” is a comparison, not proof that changing those levels improves someone’s life.
Does it work for muscle, fat loss or injury recovery?
The early human study does not establish these advertised benefits. To answer them properly, research would need to compare a clearly defined preparation with a suitable control, measure the outcome in the intended population and record harms. A study of healthy volunteers cannot automatically answer a question about an injured athlete or a person with a diagnosed hormonal disorder.
For muscle-related claims, strength and physical function matter as well as a body-composition measurement. For recovery claims, pain, function and return to activity matter. For weight-related claims, meaningful sustained outcomes and adverse effects matter. This is a way to assess a claim, not a statement that CJC-1295 has been shown to deliver those outcomes.
Before-and-after photographs are particularly weak evidence. Changes in training, food intake, sleep, other substances, lighting and measurement conditions can all complicate interpretation. A testimonial also gives little information about people who stopped because nothing improved or a problem developed.
What is known about side effects—and what is not?
The FDA’s safety review flags immune-response and impurity concerns for compounded CJC-1295, alongside reports of increased heart rate and systemic vasodilation. These are safety signals, not a reliable estimate of how often an individual user would experience harm.
The early trial’s short-term tolerability findings and a regulator’s later safety concerns answer different questions. Neither should be omitted simply because it complicates a preferred conclusion. “No serious event in this trial” does not mean “no serious event is possible”. Equally, an event associated with exposure is not automatically proven to have been caused by that exposure.
Reliable long-term risks, interaction profiles and safe wellness-use schedules are not established. It would be misleading to give an authoritative-looking list of “common” side effects with percentages when the relevant evidence does not support it. An online vial adds uncertainty about identity, strength and manufacturing quality.
Who should avoid self-use?
There is no evidence-based “suitable healthy user” checklist that clears someone for recreational CJC-1295 use. Pregnancy, breastfeeding, being under 18, significant illness, a history of cancer or endocrine disease, and taking other medicines are reasons to seek individual clinical advice—not situations in which an internet protocol can fill the gap.
This is not a licensed contraindication list: there is no approved wellness product information from which to create one. The important point is that excluding a few risk factors does not establish safety for everyone else. Do not stop prescribed medicines to make room for an experimental product.
Is CJC-1295 legal or prescribed in the UK?
CJC-1295 is not a licensed UK wellness treatment. “Unlicensed” and “illegal in every circumstance” are not equivalent. The MHRA’s specials guidance describes a restricted route for individual clinical needs under Regulation 167 of the Human Medicines Regulations 2012. That route does not authorise general consumer wellness marketing.
Product status depends on more than a research disclaimer. The MHRA considers intended use, claims, properties and presentation. A seller displaying a research label is not evidence of an authorised medicine or a suitable prescribing pathway. Puri Pharmacy does not prescribe or supply CJC-1295.

What about athletes?
The 2026 WADA Prohibited List names CJC-1295 under S2 growth hormone-releasing factors. It is prohibited both in and out of competition. Being injured or using it between seasons does not remove that restriction. Athletes should use UKAD’s official medication-checking guidance and their sport’s advice.
Can blood tests or combining it with ipamorelin solve the uncertainty?
No. A blood test can answer a specific clinical question; it cannot prove that an experimental intervention will improve health or that an online preparation is genuine. A hormone result should be interpreted in clinical context, rather than treated as a target to push higher.
Combining CJC-1295 with ipamorelin creates another intervention to evaluate. Different receptor pathways provide a possible biological rationale, but separate evidence about each compound is not a trial of the mixture. A larger hormonal response would still leave patient benefit, interactions and long-term harm unresolved.
A more useful next step for symptoms or recovery concerns
Start with the problem that led you to search. Persistent fatigue, disturbed sleep or a change in exercise tolerance should not be self-diagnosed as growth hormone deficiency. The NHS fatigue guidance describes several possible causes and when to see a GP. An injury needs a diagnosis and an appropriate rehabilitation plan.
- Describe the symptom or goal and how long it has been present.
- Bring a list of medicines, supplements and any peptides already used.
- Bring the product label or a photograph; say if the identity is uncertain.
- Ask what diagnosis is being considered and whether testing would change care.
- Ask which established options address your actual problem.
If you have already used a product and develop symptoms, explain the timing and seek medical advice. Call 999 for sudden throat or tongue swelling or breathing difficulty, in line with NHS anaphylaxis guidance. Do not wait for a routine hormone panel.
Frequently asked questions
Is CJC-1295 the same as growth hormone?
No. It is a growth hormone-releasing hormone analogue. Stimulating hormone release and administering growth hormone are different interventions, but neither distinction establishes suitability for self-use.
Does a higher IGF-1 mean better recovery?
Not by itself. A laboratory change does not establish an improvement in pain, function or return to activity.
Can the DAC study validate a “no DAC” product?
Not automatically. The exact substance and preparation need to match. Similar marketing names do not make research transferable.
Does a prescription make it permitted in sport?
No. Sporting restrictions and any Therapeutic Use Exemption requirements are separate from prescribing decisions.
Can Puri Pharmacy provide a CJC-1295 course?
No. Our role here is education and appropriate signposting, not supplying or supervising a CJC-1295 wellness course.
Key takeaways
- Early human data demonstrate hormonal activity, not established wellness benefits.
- Preparation identity matters, especially with DAC and “no DAC” claims.
- Short-term trial findings cannot certify long-term safety.
- UK medicine rules and anti-doping rules are separate checks.
- Assess the underlying symptom rather than choosing a peptide first.
Evidence summary
This summary draws on the studies and official guidance linked above.
- What human evidence shows: Early human research demonstrates changes in growth hormone and IGF-1 with the studied preparation.
- What is not established: Those changes do not establish better recovery, body composition or healthy ageing, or validate every DAC and no-DAC claim.
- Main safety uncertainties: Longer-term exposure, preparation differences and combination use remain important uncertainties.
- What would change the assessment: Trials of the exact preparation measuring relevant health or functional outcomes, with sufficient safety follow-up.
Continue reading
Follow Rahul’s peptide analysis
Subscribe to Puri Pharmacy’s health updates, including Rahul Puri’s explanations of peptide evidence, safety and UK regulation. This is an educational newsletter, not access to peptide treatment.
By subscribing, you agree to receive Puri Pharmacy’s health emails. Read our privacy policy.
Have a question about a claim? Use our contact form and include the article or study you want explained. Do not post personal health information in public comments. These articles provide education; Puri does not supply the experimental research peptides discussed here.
For symptoms or an individual treatment decision, seek appropriate clinical advice. For urgent symptoms, seek urgent medical care directly rather than waiting for a pharmacy reply.